HeliosX Group Revenue and Competitors

London, UK

Location

#4997

Growjo Ranking

Fitness

Industry

Estimated Revenue & Valuation

  • HeliosX Group's estimated annual revenue is currently $69.9M per year.(i)
  • HeliosX Group's estimated revenue per employee is $140,000

Employee Data

  • HeliosX Group has 499 Employees.(i)
  • HeliosX Group grew their employee count by 125% last year.

HeliosX Group's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Operating Officer (Interim)Reveal Email/Phone
3
Chief PharmacistReveal Email/Phone
4
Head LegalReveal Email/Phone
5
Head UX ResearchReveal Email/Phone
6
Head Creative ContentReveal Email/Phone
7
VP PeopleReveal Email/Phone
8
Head People Operations and PartnershipsReveal Email/Phone
9
Head GrowthReveal Email/Phone
10
VP FinanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15M106-9%N/AN/A
#2
$15M2418%N/AN/A
#3
$0.7M567%N/AN/A
#4
$66.6M47631%N/AN/A
#5
$3.2M23109%$3.74MN/A
#6
$3.5M25-4%N/AN/A
#7
$0.6M40%N/AN/A
#8
$9.9M71-4%$4.43MN/A
#9
$300M29745%N/AN/A
#10
$1.7M12-8%N/AN/A
Add Company

What Is HeliosX Group?

We are a group of health tech companies (RocketRx, MedExpress, Dermatica (UK/US), ZipHealth and Bloom & Halo) under one umbrella, and a rapidly growing team of c.50 sitting in the heart of Shoreditch, London. We operate a number of brands and ventures in medical, dermatology, and nutritional supplement sectors. We service over half a million patients across the UK and internationally, providing tailored consultation and personalised prescription services helping people treat a wide range of conditions. We are dedicated to improving the quality, accessibility and affordability of healthcare for every person on the planet.

keywords:N/A

N/A

Total Funding

499

Number of Employees

$69.9M

Revenue (est)

125%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M49910%N/A
#2
$137.2M499-2%N/A
#3
$104M5005%$253M
#4
$93.9M50139%N/A
#5
$202.3M50135%N/A